The estimated Net Worth of James A Harper is at least $113 mil dollars as of 30 March 2007. James Harper owns over 50,000 units of Cortexyme Inc stock worth over $112,905 and over the last 20 years James sold CRTX stock worth over $0.
James has made over 4 trades of the Cortexyme Inc stock since 2005, according to the Form 4 filled with the SEC. Most recently James bought 50,000 units of CRTX stock worth $50,000 on 30 March 2007.
The largest trade James's ever made was buying 50,000 units of Cortexyme Inc stock on 30 March 2007 worth over $50,000. On average, James trades about 5,185 units every 51 days since 2004. As of 30 March 2007 James still owns at least 57,900 units of Cortexyme Inc stock.
You can see the complete history of James Harper stock trades at the bottom of the page.
James's mailing address filed with the SEC is C/O CORCEPT THERAPEUTICS, 275 MIDDLEFIELD ROAD, SUITE A, MENLO PARK, CA, 94025.
Over the last 21 years, insiders at Cortexyme Inc have traded over $59,595,534 worth of Cortexyme Inc stock and bought 19,273,711 units worth $164,053,955 . The most active insiders traders include & Johnson Johnson & Johnson..., Farmaceutici Sp A Chiesi, eAnsbert Gadicke. On average, Cortexyme Inc executives and independent directors trade stock every 59 days with the average trade being worth of $475,426. The most recent stock trade was executed by Caryn Gordon Mc Dowell on 6 June 2022, trading 10,800 units of CRTX stock currently worth $30,888.
Cortexyme, Inc. is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer's and other degenerative diseases. Based upon the evidence generated to date, Cortexyme is currently advancing its lead therapeutic candidate, atuzaginstat (COR388), in the GAIN Trial, an ongoing Phase 2/3 clinical trial in patients with mild to moderate Alzheimer's disease. Cortexyme is targeting a specific, infectious pathogen found in the brain and other organs and tied to degeneration and inflammation in humans and animal models.
Cortexyme Inc executives and other stock owners filed with the SEC include: